Physician profile
Sharifa Baker
NPI 1811979073
$2,686.94
in general payments reported to CMS, 2019-2025
32 companies · $51.97 in 2025
The $51.97 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,696 · 2020: $616 · 2021: $37.02 · 2022: $124 · 2023: $36.34 · 2024: $125 · 2025: $51.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $345.42 | 2019-2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $316.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $205.09 | 2019-2024 | Farxiga |
| Pfizer INC. | $190.49 | 2019-2020 | |
| Allergan, INC. | $183.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.29 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $144.38 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.83 | 2019-2020 | |
| Amarin Pharma, INC. | $119.63 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.66 | 2019 | |
| Merck Sharp & Dohme LLC | $90.72 | 2019-2020 | |
| Abbvie INC. | $86.48 | 2024-2025 | |
| Amgen INC. | $73.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $57.58 | 2019-2022 | |
| Dexcom, INC. | $54.23 | 2022-2024 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $51.78 | 2019 | |
| Lilly USA, LLC | $49.57 | 2019 | |
| Astellas Pharma US INC | $43.78 | 2019 | |
| Medtronic, INC. | $34.55 | 2022 | |
| Antares Pharma, INC. | $27.63 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $26.94 | 2019 | |
| Medtronic Minimed, INC. | $26.51 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.75 | 2023 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $19.91 | 2021 | |
| Horizon Therapeutics Plc | $18.04 | 2019 | |
| Zyla Life Sciences, INC. | $16.09 | 2019 | |
| Acerus Pharmaceuticals Corporation | $15.80 | 2022 | |
| Currax Pharmaceuticals LLC | $14.13 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.09 | 2020 | |
| Kvk-Tech, INC. | $11.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharifa Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.